Brief: Organicell Completes Enrollment For Its Expanded Access Trial To Treat Covid-19 Patients With Zofin™
22/04/2021 12:38
April 22 (Reuters) - Organicell Regenerative Medicine Inc
BPSR.PK :
* ORGANICELL COMPLETES ENROLLMENT FOR ITS EXPANDED ACCESS
TRIAL TO
TREAT COVID-19 PATIENTS WITH ZOFIN™
Source text for Eikon: ID:nBw1lsCLva
Further company coverage: BPSR.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zeo Scientifix
See all newsBrief: Organicell Regenerative Says Zofin Therapy Approved By Pakistani Regulators To Be Used For A Covid-19 Patient On Compassionate Grounds
Brief: Organicell Begins Up-Listing Process On Nasdaq
Brief: Organicell Announces Positive Results Of Initial Covid-19 Zofin™ Patient Trial In India And Trial Expansion
Brief: Organicell Completes Enrollment For Its Expanded Access Trial To Treat Covid-19 Patients With Zofin™
Brief: Organicell Announces FDA Approval Of IND Application For Use Of Zofin In The Treatment Of Chronic Obstructive Pulmonary Disease